The feature article written by our CEO, Chris Molloy, explains why the future of medical innovation lies with the industry’s SMEs:
“We are familiar with the industry noise around falling productivity and return on investment in pharma R&D. We are less familiar with hearing the call of the small and medium-sized enterprise (SME) community.
With help, I believe this group can quietly develop the greatest explosion in ‘new’ biology in 50 years. Traditionally the agile, risk-taking testers of new ideas, primed to be bought and incorporated into bigger firms or to see their products developed by others, SMEs now have a new opportunity: to grow and conquer.”
Read the full article in Future Pharma online